AN2 Therapeutics, Inc. Earnings Per Share (Basic)
AN2 Therapeutics, Inc. (ANTX) reported Earnings Per Share (Basic) of -$0.18 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-11
- AN2 Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.18.
- AN2 Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.29.
- AN2 Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$0.29.
- AN2 Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.31.
- AN2 Therapeutics, Inc. earnings per share, basic for fiscal 2025 was -$1.16.
- AN2 Therapeutics, Inc. earnings per share, basic for fiscal 2024 was -$1.72.
- AN2 Therapeutics, Inc. earnings per share, basic for fiscal 2023 was -$2.74.
- AN2 Therapeutics, Inc. earnings per share, basic for fiscal 2022 was -$2.79.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.18 10-Q · filed 2026-08-11 | -$0.46 10-Q · filed 2026-08-11 | -$0.74 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$1.04 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2026-03-31 | -$0.29 10-Q · filed 2026-05-11 | -$0.58 derived: net income ÷ weighted average shares · filed 2026-05-11 | -$0.89 derived: net income ÷ weighted average shares · filed 2026-05-11 | -$1.11 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2025-12-31 | -$0.29 derived: net income ÷ weighted average shares · filed 2026-03-17 | -$0.60 derived: net income ÷ weighted average shares · filed 2026-03-17 | -$0.81 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$1.16 10-K · filed 2026-03-17 |
| 2025-09-30 | -$0.31 10-Q · filed 2025-11-12 | -$0.52 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$0.88 10-Q · filed 2025-11-12 | -$1.13 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2025-06-30 | -$0.21 10-Q · filed 2026-08-11 | -$0.57 10-Q · filed 2026-08-11 | -$0.82 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$1.25 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2025-03-31 | -$0.35 10-Q · filed 2026-05-11 | -$0.61 derived: net income ÷ weighted average shares · filed 2026-05-11 | -$1.03 derived: net income ÷ weighted average shares · filed 2026-05-11 | -$1.52 derived: net income ÷ weighted average shares · filed 2026-05-11 |
| 2024-12-31 | -$0.25 derived: net income ÷ weighted average shares · filed 2026-03-17 | -$0.68 derived: net income ÷ weighted average shares · filed 2026-03-17 | -$1.16 derived: net income ÷ weighted average shares · filed 2026-03-17 | -$1.72 10-K · filed 2026-03-17 |
| 2024-09-30 | -$0.43 10-Q · filed 2025-11-12 | -$0.91 derived: net income ÷ weighted average shares · filed 2025-11-12 | -$1.47 10-Q · filed 2025-11-12 | -$2.04 derived: net income ÷ weighted average shares · filed 2025-11-12 |
| 2024-06-30 | -$0.48 10-Q · filed 2025-08-12 | -$1.04 10-Q · filed 2025-08-12 | -$1.61 derived: net income ÷ weighted average shares · filed 2025-08-12 | -$2.25 derived: net income ÷ weighted average shares · filed 2025-08-12 |
| 2024-03-31 | -$0.56 10-Q · filed 2025-05-13 | -$1.13 derived: net income ÷ weighted average shares · filed 2025-05-13 | -$1.77 derived: net income ÷ weighted average shares · filed 2025-05-13 | -$2.52 derived: net income ÷ weighted average shares · filed 2025-05-13 |
| 2023-12-31 | -$0.57 derived: net income ÷ weighted average shares · filed 2025-03-25 | -$1.21 derived: net income ÷ weighted average shares · filed 2025-03-25 | -$1.98 derived: net income ÷ weighted average shares · filed 2025-03-25 | -$2.74 10-K · filed 2025-03-25 |
| 2023-09-30 | -$0.65 10-Q · filed 2024-11-13 | -$1.44 derived: net income ÷ weighted average shares · filed 2024-11-13 | -$2.22 10-Q · filed 2024-11-13 | -$2.84 derived: net income ÷ weighted average shares · filed 2024-11-13 |
| 2023-06-30 | -$0.81 10-Q · filed 2024-08-13 | -$1.60 10-Q · filed 2024-08-13 | -$2.21 derived: net income ÷ weighted average shares · filed 2024-08-13 | -$2.80 derived: net income ÷ weighted average shares · filed 2024-08-13 |
| 2023-03-31 | -$0.79 10-Q · filed 2024-05-14 | -$1.40 derived: net income ÷ weighted average shares · filed 2024-05-14 | -$1.99 derived: net income ÷ weighted average shares · filed 2024-05-14 | -$2.51 derived: net income ÷ weighted average shares · filed 2024-05-14 |
| 2022-12-31 | -$0.61 derived: net income ÷ weighted average shares · filed 2024-03-29 | -$1.20 derived: net income ÷ weighted average shares · filed 2024-03-29 | -$1.72 derived: net income ÷ weighted average shares · filed 2024-03-29 | -$2.79 10-K · filed 2024-03-29 |
| 2022-09-30 | -$0.59 10-Q · filed 2023-11-09 | -$1.11 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$2.21 10-Q · filed 2023-11-09 | -$3.64 derived: net income ÷ weighted average shares · filed 2023-11-09 |
| 2022-06-30 | -$0.53 10-Q · filed 2023-08-10 | -$1.74 10-Q · filed 2023-08-10 | -$3.47 derived: net income ÷ weighted average shares · filed 2023-08-10 | -$5.47 derived: net income ÷ weighted average shares · filed 2023-08-10 |
| 2022-03-31 | -$2.98 10-Q · filed 2023-05-11 | -$6.49 derived: net income ÷ weighted average shares · filed 2023-05-11 | -$9.84 derived: net income ÷ weighted average shares · filed 2023-05-11 | -$12.50 derived: net income ÷ weighted average shares · filed 2023-05-11 |
| 2021-12-31 | -$3.57 derived: net income ÷ weighted average shares · filed 2023-03-29 | -$6.92 derived: net income ÷ weighted average shares · filed 2023-03-29 | -$9.55 derived: net income ÷ weighted average shares · filed 2023-03-29 | -$10.64 10-K · filed 2023-03-29 |
| 2021-09-30 | -$3.35 10-Q · filed 2022-11-09 | -$5.98 derived: net income ÷ weighted average shares · filed 2022-11-09 | -$7.06 10-Q · filed 2022-11-09 | |
| 2021-06-30 | -$2.62 10-Q · filed 2022-08-11 | -$3.70 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |